Follow The Filings

PMCB PharmaCyte Biotech

PharmaCyte Biotech earnings company data as of 6:20 AM ET 9/15

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 21 Sep EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by PMCB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PMCB insider trades
  • $129K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Joshua Silverman CEO
    Buy
    $80K 100,000 shares at $0.8000 +32% to stake
    Traded Jan 5–7 Filed Jan 7
    ↗
  2. Jonathan Schechter Director
    Buy
    $48K 60,000 shares at $0.8000 +45% to stake
    Traded Jan 5–7 Filed Jan 7
    ↗

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants and 5 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
8-K 4.01,9.01 Filing Doc
10-Q FORM 10-Q FOR JUL 2026 Filing Doc
10-K FORM 10-K FOR APRIL 2026 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q FORM 10-Q FOR JAN 2026 Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q FORM 10-Q FOR OCT 2025 Filing Doc
8-K 3.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K/A 9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
10-Q FORM 10-Q FOR JUL 2025 Filing Doc
8-K 1.01,2.01,7.01,9.01 Filing Doc
8-K 1.01,3.02,7.01,9.01 Filing Doc
10-K FORM 10-K FOR APR 2025 Filing Doc
8-K 5.07 Filing Doc
10-Q FORM 10-Q FOR JAN 2025 Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
DEFA14A FORM DEFA 14A Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.